[{"data":1,"prerenderedAt":34},["ShallowReactive",2],{"project-dd0cb69969ef5fe800dd3ecb7cfe8eb3":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"landing_hospitals":14,"tech_company_name":21,"view_count":22,"favorite_count":23,"is_favorite":24,"approval_no":25,"approval_date":26,"regulatory_level":27,"valid_until":26,"filing_date":28,"intro":29,"detail_desc":30,"target_population":31,"compliance_list":32,"process":33},"dd0cb69969ef5fe800dd3ecb7cfe8eb3","人脐带源间充质干细胞应用肝硬化技术",[7],"肝硬化","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/covers/cover-04.jpg","干细胞应用",[7],"14.9万/次","海南博鳌超级医院",[12],[15],{"id":16,"name":12,"level":17,"city":18,"province":19,"dept":20},"18b1344f69ef568500d8f450538a570d","三甲","琼海市","海南","细胞治疗中心","中源协和细胞基因工程股份有限公司",206,1,false,"乐城第四批获批","","低风险","2025年","\u003Cp>人脐带源间充质干细胞静脉回输用于肝硬化患者的肝功能改善与抗纤维化治疗。\u003C/p>\u003Cp>\u003Cb>适应症\u003C/b>:肝硬化(代偿期 / 失代偿期)\u003Cbr/>\u003Cb>技术类型\u003C/b>:干细胞应用\u003Cbr/>\u003Cb>批次\u003C/b>:乐城第四批获批\u003C/p>","人脐带源间充质干细胞静脉回输用于肝硬化患者的肝功能改善与抗纤维化治疗。",[],[],[],1780973403236]